These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
249 related articles for article (PubMed ID: 23623990)
81. Mechanism of toxicity in rotenone models of Parkinson's disease. Sherer TB; Betarbet R; Testa CM; Seo BB; Richardson JR; Kim JH; Miller GW; Yagi T; Matsuno-Yagi A; Greenamyre JT J Neurosci; 2003 Nov; 23(34):10756-64. PubMed ID: 14645467 [TBL] [Abstract][Full Text] [Related]
82. Piperine induces autophagy by enhancing protein phosphotase 2A activity in a rotenone-induced Parkinson's disease model. Liu J; Chen M; Wang X; Wang Y; Duan C; Gao G; Lu L; Wu X; Wang X; Yang H Oncotarget; 2016 Sep; 7(38):60823-60843. PubMed ID: 27572322 [TBL] [Abstract][Full Text] [Related]
83. Delayed gastric emptying and enteric nervous system dysfunction in the rotenone model of Parkinson's disease. Greene JG; Noorian AR; Srinivasan S Exp Neurol; 2009 Jul; 218(1):154-61. PubMed ID: 19409896 [TBL] [Abstract][Full Text] [Related]
84. The Drosophila hep pathway mediates Lrrk2-induced neurodegeneration. Yang D; Thomas JM; Li T; Lee Y; Liu Z; Smith WW Biochem Cell Biol; 2018 Aug; 96(4):441-449. PubMed ID: 29268033 [TBL] [Abstract][Full Text] [Related]
86. Evidence of neuroprotective effects of saffron and crocin in a Drosophila model of parkinsonism. Rao SV; Muralidhara ; Yenisetti SC; Rajini PS Neurotoxicology; 2016 Jan; 52():230-42. PubMed ID: 26705857 [TBL] [Abstract][Full Text] [Related]
88. HDAC inhibitor trichostatin A-inhibited survival of dopaminergic neuronal cells. Wang Y; Wang X; Liu L; Wang X Neurosci Lett; 2009 Dec; 467(3):212-6. PubMed ID: 19835929 [TBL] [Abstract][Full Text] [Related]
89. A neuroprotective role of the human uncoupling protein 2 (hUCP2) in a Drosophila Parkinson's disease model. Islam R; Yang L; Sah M; Kannan K; Anamani D; Vijayan C; Kwok J; Cantino ME; Beal MF; Fridell YW Neurobiol Dis; 2012 Apr; 46(1):137-46. PubMed ID: 22266335 [TBL] [Abstract][Full Text] [Related]
90. Effects of pharmacological agents upon a transgenic model of Parkinson's disease in Drosophila melanogaster. Pendleton RG; Parvez F; Sayed M; Hillman R J Pharmacol Exp Ther; 2002 Jan; 300(1):91-6. PubMed ID: 11752102 [TBL] [Abstract][Full Text] [Related]
91. Depressive-like behaviors alterations induced by intranigral MPTP, 6-OHDA, LPS and rotenone models of Parkinson's disease are predominantly associated with serotonin and dopamine. Santiago RM; Barbieiro J; Lima MM; Dombrowski PA; Andreatini R; Vital MA Prog Neuropsychopharmacol Biol Psychiatry; 2010 Aug; 34(6):1104-14. PubMed ID: 20547199 [TBL] [Abstract][Full Text] [Related]
92. The dietary supplementation of nordihydroguaiaretic acid (NDGA) delayed the loss of climbing ability in Drosophila model of Parkinson's disease. Siddique YH; Ara G; Jyoti S; Afzal M J Diet Suppl; 2012 Mar; 9(1):1-8. PubMed ID: 22432798 [TBL] [Abstract][Full Text] [Related]
93. Effect of Oleracein E, a Neuroprotective Tetrahydroisoquinoline, on Rotenone-Induced Parkinson's Disease Cell and Animal Models. Sun H; He X; Liu C; Li L; Zhou R; Jin T; Yue S; Feng D; Gong J; Sun J; Ji J; Xiang L ACS Chem Neurosci; 2017 Jan; 8(1):155-164. PubMed ID: 27731637 [TBL] [Abstract][Full Text] [Related]
94. Behavioral alterations in rotenone model of Parkinson's disease: attenuation by co-treatment of centrophenoxine. Nehru B; Verma R; Khanna P; Sharma SK Brain Res; 2008 Mar; 1201():122-7. PubMed ID: 18308296 [TBL] [Abstract][Full Text] [Related]
95. Bilateral upregulation of α-synuclein expression in the mouse substantia nigra by intracranial rotenone treatment. Carriere CH; Kang NH; Niles LP Exp Toxicol Pathol; 2017 Feb; 69(2):109-114. PubMed ID: 27986376 [TBL] [Abstract][Full Text] [Related]
96. The peptidyl-prolyl isomerase Pin1 up-regulation and proapoptotic function in dopaminergic neurons: relevance to the pathogenesis of Parkinson disease. Ghosh A; Saminathan H; Kanthasamy A; Anantharam V; Jin H; Sondarva G; Harischandra DS; Qian Z; Rana A; Kanthasamy AG J Biol Chem; 2013 Jul; 288(30):21955-71. PubMed ID: 23754278 [TBL] [Abstract][Full Text] [Related]
97. Epigenetic targeting of histone deacetylase: therapeutic potential in Parkinson's disease? Harrison IF; Dexter DT Pharmacol Ther; 2013 Oct; 140(1):34-52. PubMed ID: 23711791 [TBL] [Abstract][Full Text] [Related]
98. D-beta-hydroxybutyrate protects dopaminergic SH-SY5Y cells in a rotenone model of Parkinson's disease. Imamura K; Takeshima T; Kashiwaya Y; Nakaso K; Nakashima K J Neurosci Res; 2006 Nov; 84(6):1376-84. PubMed ID: 16917840 [TBL] [Abstract][Full Text] [Related]
99. JM-20, a novel hybrid molecule, protects against rotenone-induced neurotoxicity in experimental model of Parkinson's disease. Fonseca-Fonseca LA; Wong-Guerra M; Ramírez-Sánchez J; Montano-Peguero Y; Padrón Yaquis AS; Rodríguez AM; da Silva VDA; Costa SL; Pardo-Andreu GL; Núñez-Figueredo Y Neurosci Lett; 2019 Jan; 690():29-35. PubMed ID: 30304707 [TBL] [Abstract][Full Text] [Related]
100. Melatonin Mitigates Rotenone-Induced Oxidative Stress and Mitochondrial Dysfunction in the Rasheed MZ; Khatoon R; Talat F; Alam MM; Tabassum H; Parvez S ACS Omega; 2023 Feb; 8(8):7279-7288. PubMed ID: 36872990 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]